GlassScriptPhysician profile
Lisa Grana
NPI 1548229586
$2,546.88
in general payments reported to CMS, 2019-2025
26 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $45.22 · 2021: $127 · 2022: $746 · 2023: $442 · 2024: $724 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $844 · Honoraria: $550 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $843.99 |
| Honoraria | $550.00 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $573.43 | 2022-2024 | |
| Hologic Sales and Service, LLC | $557.47 | 2019-2024 | Acessa Provu System, Coolseal Generator, Myosure Tissue Removal Device |
| Pfizer INC. | $213.09 | 2019-2025 | |
| Caldera Medical, INC | $206.49 | 2022 | |
| Astellas Pharma US INC | $164.95 | 2023-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $130.26 | 2019-2023 | |
| Coopersurgical, INC. | $75.05 | 2021-2025 | Endosee, Paragard T 380a |
| Mayne Pharma Commercial LLC | $67.20 | 2022-2025 | |
| Therapeuticsmd, INC. | $66.29 | 2019-2021 | |
| Channel Medsystems, INC. | $57.54 | 2022 | |
| Evofem Biosciences, INC. | $57.41 | 2021-2025 | Solosec, Phexx, Phexxi |
| Biogen, INC. | $52.35 | 2025 | Zurzuvae |
| Shield Therapeutics INC | $41.35 | 2022 | |
| Myovant Sciences INC. | $38.64 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.50 | 2022-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $35.99 | 2022-2023 | |
| Duchesnay USA Incorporated | $35.55 | 2019 | |
| Avion Pharmaceuticals | $31.04 | 2022-2023 | Balcoltra |
| Roche Diagnostics Corporation | $24.69 | 2019 | |
| Dexcom, INC. | $14.63 | 2024 | Dexcom G6 Transmitter |
| Minerva Surgical, INC | $14.56 | 2021 | |
| Amag Pharmaceuticals, INC. | $13.97 | 2019 | |
| Millicent US INC | $13.35 | 2024 | |
| Mission Pharmacal Company | $12.24 | 2020 | |
| Lupin INC. | $11.84 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Grana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.